Myelofibrosis

MYELOFIBROSIS

primary myelofibrosis: Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of approximately 1 case per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Hospital Discharge: ICD-10 C94.5

Hospital discharge: ICD-9 2387A

Hospital discharge: ICD-8 209

Cause of death: ICD-10 C94.5

Cause of death: ICD-9 2387A

Cause of death: ICD-8 209

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions H.D: 10, 8, 9 ; C.O.D: 10, 8, 9

Check minimum number of events None

Include endpoints None

MYELOFIBROSIS

Extra metadata

First used in FinnGen datafreeze DF2, additional

Similar endpoints

↥

List of similar endpoints to Myelofibrosis based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	15	5	10
Unadjusted prevalence (%)	0.00	0.00	0.01
Mean age at first event (years)	47.61	32.65	55.09

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	-	-	-	-
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: MYELOFIBROSIS – Myelofibrosis
GWS hits:

Survival analyses between endpoints

↥

Plot

before Myelofibrosis
after Myelofibrosis

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Myelofibrosis

↥